Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ajay Chavan, Vimal Kumar Paliwal, Vivek Singh
No abstract text is available yet for this article.
June 5, 2023: JAMA Neurology
#2
JOURNAL ARTICLE
Louis R Caplan
No abstract text is available yet for this article.
June 5, 2023: JAMA Neurology
#3
JOURNAL ARTICLE
Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, Francesco Patti, Francois Grand'Maison, Suzanne Hodgkinson, Pierre Grammond, Jeannette Lechner-Scott, Ernest Butler, Alexandre Prat, Marc Girard, Pierre Duquette, Richard A L Macdonell, Bianca Weinstock-Guttman, Serkan Ozakbas, Mark Slee, Maria Jose Sa, Vincent Van Pesch, Michael Barnett, Bart Van Wijmeersch, Oliver Gerlach, Julie Prevost, Murat Terzi, Cavit Boz, Guy Laureys, Liesbeth Van Hijfte, Allan G Kermode, Justin Garber, Bassem Yamout, Samia J Khoury, Daniel Merlo, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
IMPORTANCE: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses. OBJECTIVES: To compare the effectiveness and persistence of dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis (RRMS) who discontinued natalizumab. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, patient data were collected from the MSBase registry between June 15, 2010, and July 6, 2021...
June 5, 2023: JAMA Neurology
#4
JOURNAL ARTICLE
Eric E Smith, Lisa C Silbert
No abstract text is available yet for this article.
May 30, 2023: JAMA Neurology
#5
JOURNAL ARTICLE
Michelle C Johansen, Wen Ye, Alden Gross, Rebecca F Gottesman, Dehua Han, Rachael Whitney, Emily M Briceño, Bruno J Giordani, Supriya Shore, Mitchell S V Elkind, Jennifer J Manly, Ralph L Sacco, Alison Fohner, Michael Griswold, Bruce M Psaty, Stephen Sidney, Jeremy Sussman, Kristine Yaffe, Andrew E Moran, Susan Heckbert, Timothy M Hughes, Andrzej Galecki, Deborah A Levine
IMPORTANCE: The magnitude of cognitive change after incident myocardial infarction (MI) is unclear. OBJECTIVE: To assess whether incident MI is associated with changes in cognitive function after adjusting for pre-MI cognitive trajectories. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included adults without MI, dementia, or stroke and with complete covariates from the following US population-based cohort studies conducted from 1971 to 2019: Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, Cardiovascular Health Study, Framingham Offspring Study, Multi-Ethnic Study of Atherosclerosis, and Northern Manhattan Study...
May 30, 2023: JAMA Neurology
#6
JOURNAL ARTICLE
Sanjana Salwi
No abstract text is available yet for this article.
May 30, 2023: JAMA Neurology
#7
JOURNAL ARTICLE
Steven J Warach, Anna Ranta, Joosup Kim, Shlee S Song, Adam Wallace, James Beharry, Daniel Gibson, Dominique A Cadilhac, Christopher F Bladin, Timothy J Kleinig, Jackson Harvey, Logesh Palanikumar, Vinodh T Doss, Ruth Marescalco, John N Fink, Alicia Tyson, Konrad H Schlick, Lydia Noh, Duncan Wilson, Sonia Figueroa, Marco A Pech, Laurie B Paletz, Maya K Lewis, Marissa Castro, Daniel H Sahlein, E Frank Lafranchise, Justin Sandall, Kaiz S Asif, Scott R Geraghty, Paul A Cullis, Tim Malisch, Terry A Neill, Marian P LaMonte, Bruce C V Campbell, Teddy Y Wu
IMPORTANCE: Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysis based on evidence from randomized comparisons to alteplase as well as for its practical advantages. There have been no significant differences in symptomatic intracranial hemorrhage (sICH) reported from randomized clinical trials or published case series for the 0.25-mg/Kg dose...
May 30, 2023: JAMA Neurology
#8
JOURNAL ARTICLE
Joanna M Wardlaw, Lisa J Woodhouse, Iris I Mhlanga, Katherine Oatey, Anna K Heye, John Bamford, Vera Cvoro, Fergus N Doubal, Timothy England, Ahamad Hassan, Alan Montgomery, John T O'Brien, Christine Roffe, Nikola Sprigg, David J Werring, Philip M Bath
IMPORTANCE: Cerebral small vessel disease (cSVD) is a common cause of stroke (lacunar stroke), is the most common cause of vascular cognitive impairment, and impairs mobility and mood but has no specific treatment. OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke. DESIGN, SETTING, AND PARTICIPANTS: The Lacunar Intervention Trial-2 (LACI-2) was an investigator-initiated, open-label, blinded end-point, randomized clinical trial with a 2 × 2 factorial design...
May 24, 2023: JAMA Neurology
#9
JOURNAL ARTICLE
David B Reuben, Gary Epstein-Lubow, Nora Super
No abstract text is available yet for this article.
May 22, 2023: JAMA Neurology
#10
JOURNAL ARTICLE
Nadinda A M van der Ende, Bob Roozenbeek, Lucas E M Smagge, Sven P R Luijten, Leo A M Aerden, Petra Kraayeveld, Ido R van den Wijngaard, Geert J Lycklama À Nijeholt, Heleen M den Hertog, H Zwenneke Flach, Alida A Postma, Stefan D Roosendaal, G Menno Krietemeijer, Lonneke S F Yo, Moniek P M de Maat, Daan Nieboer, Gregory J Del Zoppo, William J Meurer, Hester F Lingsma, Aad van der Lugt, Diederik W J Dippel
IMPORTANCE: Dual thrombolytic treatment with small bolus alteplase and mutant prourokinase has the potential to be a safer and more efficacious treatment for ischemic stroke than alteplase alone because mutant prourokinase is designed to act only on degraded fibrin without affecting circulating fibrinogen. OBJECTIVE: To assess the safety and efficacy of this dual thrombolytic treatment compared with alteplase. DESIGN, SETTING, AND PARTICIPANTS: This controlled, open-label randomized clinical trial with a blinded end point was conducted from August 10, 2019, to March 26, 2022, with a total follow-up of 30 days...
May 22, 2023: JAMA Neurology
#11
JOURNAL ARTICLE
Roula Ghaoui, Samuel Curtis, Karin S Kassahn
No abstract text is available yet for this article.
May 22, 2023: JAMA Neurology
#12
JOURNAL ARTICLE
Ruben Smith, Douglas Hägerström, Daria Pawlik, Gregory Klein, Jonas Jögi, Tomas Ohlsson, Erik Stomrud, Oskar Hansson
IMPORTANCE: It is important to determine the added clinical value for tau positron emission tomography (PET) in the diagnostic workup of patients with cognitive symptoms before widespread implementation in clinical practice. OBJECTIVE: To prospectively study the added clinical value of PET detecting tau pathology in Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study (Swedish BioFINDER-2 study) took place from May 2017 through September 2021...
May 22, 2023: JAMA Neurology
#13
JOURNAL ARTICLE
Dalia L Rotstein, Tirisham V Gyang, Daniel Ontaneda
No abstract text is available yet for this article.
May 15, 2023: JAMA Neurology
#14
JOURNAL ARTICLE
Michael Hittle, William J Culpepper, Annette Langer-Gould, Ruth Ann Marrie, Gary R Cutter, Wendy E Kaye, Laurie Wagner, Barbara Topol, Nicholas G LaRocca, Lorene M Nelson, Mitchell T Wallin
IMPORTANCE: Racial, ethnic, and geographic differences in multiple sclerosis (MS) are important factors to assess when determining the disease burden and allocating health care resources. OBJECTIVE: To calculate the US prevalence of MS in Hispanic, non-Hispanic Black (hereafter referred to as Black), and non-Hispanic White individuals (hereafter referred to as White) stratified by age, sex, and region. DESIGN, SETTING, AND PARTICIPANTS: A validated algorithm was applied to private, military, and public (Medicaid and Medicare) administrative health claims data sets to identify adult cases of MS between 2008 and 2010...
May 15, 2023: JAMA Neurology
#15
JOURNAL ARTICLE
Jeffrey A Cohen, Anne H Cross
No abstract text is available yet for this article.
May 15, 2023: JAMA Neurology
#16
JOURNAL ARTICLE
Samuel M Goldman, Frances M Weaver, Kevin T Stroupe, Lishan Cao, Beverly Gonzalez, Kalea Colletta, Ethan G Brown, Caroline M Tanner
IMPORTANCE: An increased risk of Parkinson disease (PD) has been associated with exposure to the solvent trichloroethylene (TCE), but data are limited. Millions of people in the US and worldwide are exposed to TCE in air, food, and water. OBJECTIVE: To test whether the risk of PD is higher in veterans who served at Marine Corps Base Camp Lejeune, whose water supply was contaminated with TCE and other volatile organic compounds (VOCs), compared with veterans who did not serve on that base...
May 15, 2023: JAMA Neurology
#17
JOURNAL ARTICLE
E Ray Dorsey, J Timothy Greenamyre, Allison W Willis
No abstract text is available yet for this article.
May 15, 2023: JAMA Neurology
#18
JOURNAL ARTICLE
Juntao Yin, Wan Wang, Yuqing Wei
No abstract text is available yet for this article.
May 8, 2023: JAMA Neurology
#19
JOURNAL ARTICLE
Daniele Altomare, Frederik Barkhof, Camilla Caprioglio, Lyduine E Collij, Philip Scheltens, Isadora Lopes Alves, Femke Bouwman, Johannes Berkhof, Ingrid S van Maurik, Valentina Garibotto, Christian Moro, Julien Delrieu, Pierre Payoux, Laure Saint-Aubert, Anne Hitzel, José Luis Molinuevo, Oriol Grau-Rivera, Juan Domingo Gispert, Alexander Drzezga, Frank Jessen, Philip Zeyen, Agneta Nordberg, Irina Savitcheva, Vesna Jelic, Zuzana Walker, Paul Edison, Jean-François Demonet, Rossella Gismondi, Gill Farrar, Andrew W Stephens, Giovanni B Frisoni
IMPORTANCE: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. OBJECTIVE: To assess the clinical effect of amyloid PET in memory clinic patients. DESIGN, SETTING, AND PARTICIPANTS: The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics...
May 8, 2023: JAMA Neurology
#20
JOURNAL ARTICLE
Antoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, Gregory Klein, Edilio Borroni, Matteo Tonietto, Olof Strandberg, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Michael J Pontecorvo, Leonardo Iaccarino, Erik Stomrud, Rik Ossenkoppele, Ruben Smith, Oskar Hansson
IMPORTANCE: Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of participant-specific (individualized) regions of interest (ROIs) is superior to conventional approaches where the same ROI (group-level) is used for each participant. OBJECTIVE: To compare group- and participant-level ROIs in participants at different stages of the AD clinical continuum in terms of annual percentage change in tau-PET standardized uptake value ratio (SUVR) and sample size requirements...
May 8, 2023: JAMA Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
